TAS102

Phase 2Small molecule

UUniversity of Wisconsin, Madison

TAS102 is one of 6 small molecule programs targeting Gastric Cancer (GC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric Cancer (GC)Not yet recruiting

Gastric Cancer (GC)Phase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Gastric Cancer (GC)

#DrugCompanyPhaseTrials

Injectafer

AAmerican Regent, Inc.

Approved

1 2

Venofer

AAmerican Regent, Inc.

Approved

1 3

SHR-1701

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 4

TAS102

UUniversity of Wisconsin, Madison

Phase 2

1 5

NK510

BBase Therapeutics (Shanghai) Co., Ltd.

Phase 1

1 6

Retlirafusp Alfa

TTang-Du Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Gastric Cancer (GC)

NCT07913165

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT05854498

Clinical

Trials by Indication[1]

Gastric Cancer (GC)1 trial

An Open-Label, Single-Arm, Single-Center Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Refractory to ≥2 Prior Lines of Chemotherapy

Not yet recruiting·TTao Zhang·Phase 2·NCT07913165·36 enrolled

Metastatic Colorectal Cancer1 trial

Phase II Study of Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT05854498·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TAS102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAS102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAS102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Wisconsin, Madison company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Wisconsin, Madison

TAS102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Gastric Cancer (GC)1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News